J0577 NDC Crosswalk, Billing Units, ASP Payment & Medicare Reimbursement

📋 J0577 summary

J0577 is a HCPCS Level II J-code used to bill brixadi, 7 days or less, billed per Less than or equal to 7 days of therapy. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J0577: Brixadi(J0577), Brixadi

Code J0577 Billing unit Less than or equal to 7 days of therapy Payment limit $430.576/unit NDC-Crosswalk 4 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ0577

DescriptorInj, brixadi, 7 days or less

Billing unitLess than or equal to 7 days of therapy

Payment limit / unit$430.576

Est. ASP / unit$406.204 est.

Mapped NDCs4

Data periodQ3 2026

Last updated2026-08-20

💊 About Buprenorphine DRUG GUIDE

Buprenorphine sublingual tablets are used to treat opioid dependence — that means a physical and psychological reliance on opioids.

It is particularly preferred during the induction phase, which is the first stage of treatment when a person is just starting their recovery program.This medication is not meant to be used alone.

It works best as part of a complete treatment plan that includes counseling and psychosocial support — think therapy, peer support, and other recovery resources working together with the medication.

Read the full Buprenorphine drug guide →

Clinical overview from our editorial drug guide for Buprenorphine. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).

Medicare payment limit / unit

$430.576

Est. ASP / unit

$406.204 est.

Est. after 2% sequester

$421.964

HCPCS dosage

Less than or equal to 7 days of therapy

The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J0577 = 7 days. Enter a regimen to convert dose → billing units and project a full course.

Dose per administration (days) Frequency — every days Number of doses NDC / package billed (optional)

Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J0577 WITH EST. MEDICARE PAY

4 NDCs map to J0577. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($430.576/unit) × that package's bill units.

NDC (11-digit)	Drug	Labeler	Package	Strength	Bill units	Est. pay / pkg	NADAC / unit	Status	Source
58284-0208-01	BRIXADI BUPRENORPHINE 8 mg/.16mL INJECTION	Braeburn	1 SYRINGE, GLASS in 1 CARTON (58284-208-01...	8 mg/.16mL	1	$430.58	—	● Active	CMS + PDAC
58284-0216-01	BRIXADI BUPRENORPHINE 16 mg/.32mL INJECTION	Braeburn	1 SYRINGE, GLASS in 1 CARTON (58284-216-01...	16 mg/.32mL	1	$430.58	—	● Active	CMS + PDAC
58284-0224-01	BRIXADI BUPRENORPHINE 24 mg/.48mL INJECTION	Braeburn	1 SYRINGE, GLASS in 1 CARTON (58284-224-01...	24 mg/.48mL	1	$430.58	—	● Active	CMS + PDAC
58284-0232-01	BRIXADI BUPRENORPHINE 32 mg/.64mL INJECTION	Braeburn	1 SYRINGE, GLASS in 1 CARTON (58284-232-01...	32 mg/.64mL	1	$430.58	—	● Active	CMS + PDAC

NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

⚠️ Don't confuse J0577 with… RELATED CODES

Adjacent HCPCS codes that share an ingredient or formulation with J0577. Billing units and payment limits differ — confirm the exact code, strength and form before billing.

Code	Descriptor	Billing unit	Payment limit / unit	How it differs from J0577
Q9991	Buprenorph xr 100 mg or less	Less than or equal to 100 MG	$2,068.155	Different billing unit — Less than or equal to 100 MG vs Less than or equal to 7 days of therapy
Q9992	Buprenorphine xr over 100 mg	Greater than 100 MG	$2,068.155	Different billing unit — Greater than 100 MG vs Less than or equal to 7 days of therapy
J0578	BUPRENORPHINE	Greater than 7 days and up to 28 days of therapy	$1,722.305	Different billing unit — Greater than 7 days and up to 28 days of therapy vs Less than or equal to 7 days of therapy
J0592	Buprenorphine hydrochloride	0.1 MG	$4.474	Different billing unit — 0.1 MG vs Less than or equal to 7 days of therapy

Related codes matched on shared ingredient (CMS Medicare Part B Spending feed). Billing units and payment limits from the CMS ASP Pricing File. Always verify the precise HCPCS code for the product and strength administered.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period

Total Part B spend

$9.6K

Claims

29

Beneficiaries

17

Spend / beneficiary

$563.46

Spend / claim

$330.30

Trend by period

Where J0577 ranks among Part B drugs · 2026 (Q1) · neighbors ±5

Total spending — #689 of 824

#684 LACTATED RINGERS J7120 $10.9K #685 BUSULFAN* J0594 $10.6K #686 VINORELBINE TARTRATE J9390 $10.5K #687 DERMA-GIDE, 1 SQ CM*... Q4203 $9.9K #688 ALBUTEROL SULFATE(J7... J7612 $9.8K #689 BRIXADI(J0577) J0577 $9.6K #690 DEXTROSE IN WATER(J7... J7060 $9.4K #691 CEFTAZIDIME* J0713 $9.3K #692 BLEOMYCIN SULFATE J9040 $9.1K #693 MORPHINE SULFATE(J22... J2270 $8.2K #694 BUPIVACAINE HCL* J0665 $8.1K

Total claims — #744 of 824

#739 ERZOFRI J2428 31 #740 TIGAN J3250 31 #741 LEVOTHYROXINE SODIUM... J0650 30 #742 TEMODAR J9328 30 #743 CYGNUS, PER SQ CM** Q4170 30 #744 BRIXADI(J0577) J0577 29 #745 HYPERRHO* J2790 29 #746 ZIEXTENZO Q5120 29 #747 HYPERHEP B* 90371 28 #748 SPEVIGO J1747 28 #749 TIGECYCLINE* J3243 28

Full breakdown by period (2)

Period	Total spend	Beneficiaries	Claims	$/beneficiary	$/claim
2026 (Q1)	$9.6K	17	29	$563.46	$330.30
2025 (Q1-Q4)	$18K	35	66	$514.21	$272.69

Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.

Allowed charges

$0.20

Medicare paid

$744.54

Submitted services

52

Denial rate

61.5%

Allowed / service

$0.01

Submitted charges

$0.52

Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

📊 What bills under J0577

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient

BUPRENORPHINE 4

NDC products by labeler

Braeburn Inc. 4

🔗 Related NDC directory pages

🧪 All Buprenorphine NDCsIngredient 🏭 All Braeburn labeler NDCsLabeler 58284 📚 All Partial Opioid Agonist NDCsDrug class

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.

HCPCS code & descriptor

CMS HCPCS Level II code file

Not available in current dataset

Payment limit & billing unit

CMS Medicare Part B ASP Pricing File (quarterly)

Q3 2026 · as of 2026-08-20

NDC ↔ HCPCS crosswalk

CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)

4 NDCs mapped

NADAC acquisition cost

CMS National Average Drug Acquisition Cost (weekly)

Not available for mapped NDCs

Utilization & spend

CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners

Latest data year 2026

Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J0577 billing FAQ

What is HCPCS code J0577?

J0577 is a HCPCS Level II J-code used to bill Inj, brixadi, 7 days or less under Medicare Part B and most medical (not pharmacy) benefits.

What is the billing unit for J0577?

One unit of J0577 represents Less than or equal to 7 days of therapy. Report the number of units equal to the dose administered divided by Less than or equal to 7 days of therapy.

How many units of J0577 should I bill?

Divide the dose administered by the code's unit size (Less than or equal to 7 days of therapy) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.

How much does Medicare pay for J0577?

The Medicare Part B payment limit is $430.576 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $421.964 per unit. Payment limits are revised quarterly.

Which NDCs bill under J0577?

4 NDCs currently map to J0577 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.

Does a crosswalk mean J0577 is covered?

No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.

J0577 – Inj, brixadi, 7 days or less · NDC Crosswalk & Billing Units